Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2018

05.01.2018 | Original Article

Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy

verfasst von: Hironori Fukuda, Toshio Takagi, Tsunenori Kondo, Kazuhiko Yoshida, Satoru Shimizu, Yoji Nagashima, Kazunari Tanabe

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of the present study was to evaluate the prognostic significance of the Glasgow Prognostic Score (GPS) in metastatic renal cell carcinoma (mRCC) patients treated by cytoreductive nephrectomy (CN), and the accuracy of the GPS as a prognostic factor.

Methods

We retrospectively analyzed the data of patients who underwent CN for mRCC between March 1984 and August 2015. In accordance with the GPS criteria, the patients were classified into three groups: GPS 0: C-reactive protein (CRP) ≤ 1.0 mg/dl and albumin ≥ 3.5 g/dl; GPS 1: CRP > 1.0 mg/dl or albumin < 3.5 g/dl; and GPS 2: CRP > 1.0 mg/dl and albumin < 3.5 g/dl.

Results

We enrolled 170 patients (72% male; median age 63.5 years). Fifty-six (33%), 67 (39%), and 47 (28%) patients had a GPS of 0, 1, and 2, respectively. The median overall survivals after CN were 52.4, 19.1, and 8.9 months for patients with a GPS of 0, 1, and 2, respectively (P < 0.0001). In addition to the GPS, Eastern Cooperative Oncology Group performance status (ECOG-PS), Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis were included in the Cox hazards regression model. Multivariate analysis of these factors revealed that the GPS was an independent prognostic factor of overall survival (P < 0.0001). Harrell’s concordance index in the multivariate prognostic model based on ECOG-PS, MSKCC risk criteria, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis was 0.609, which increased to 0.652 after the inclusion of the GPS.

Conclusions

GPS represents an independent prognostic factor for patients who undergo CN for mRCC.
Literatur
1.
Zurück zum Zitat Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659CrossRefPubMed Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659CrossRefPubMed
13.
Zurück zum Zitat Debra J, Thomas EH, Charles LC et al (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on heamodialysis. BJU Int 108(8):1279–1283CrossRef Debra J, Thomas EH, Charles LC et al (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on heamodialysis. BJU Int 108(8):1279–1283CrossRef
18.
Zurück zum Zitat Sobin LH, Gospodarowicz M, Wittekind CH (2009) Kidney (ICD-O C64). TNM classification of malignant tumors, 7th edn. Wiley-Liss, New York, pp 255–257 Sobin LH, Gospodarowicz M, Wittekind CH (2009) Kidney (ICD-O C64). TNM classification of malignant tumors, 7th edn. Wiley-Liss, New York, pp 255–257
21.
Zurück zum Zitat Harrell FE Jr, Califf RM, Pryor DB et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543–2546CrossRefPubMed Harrell FE Jr, Califf RM, Pryor DB et al (1982) Evaluating the yield of medical tests. JAMA 247(18):2543–2546CrossRefPubMed
27.
Zurück zum Zitat Koo AS, Armstrong C, Bochner B et al (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother CII 35(2):97–105CrossRefPubMed Koo AS, Armstrong C, Bochner B et al (1992) Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother CII 35(2):97–105CrossRefPubMed
28.
Zurück zum Zitat Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250(2):607–610CrossRefPubMed Miki S, Iwano M, Miki Y et al (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250(2):607–610CrossRefPubMed
29.
Zurück zum Zitat Gauldie J, Richards C, Harnish D et al (1987) Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84(20):7251–7255CrossRefPubMedPubMedCentral Gauldie J, Richards C, Harnish D et al (1987) Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84(20):7251–7255CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy
verfasst von
Hironori Fukuda
Toshio Takagi
Tsunenori Kondo
Kazuhiko Yoshida
Satoru Shimizu
Yoji Nagashima
Kazunari Tanabe
Publikationsdatum
05.01.2018
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1221-z

Weitere Artikel der Ausgabe 3/2018

International Journal of Clinical Oncology 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.